JP2007520453A5 - - Google Patents

Download PDF

Info

Publication number
JP2007520453A5
JP2007520453A5 JP2006539874A JP2006539874A JP2007520453A5 JP 2007520453 A5 JP2007520453 A5 JP 2007520453A5 JP 2006539874 A JP2006539874 A JP 2006539874A JP 2006539874 A JP2006539874 A JP 2006539874A JP 2007520453 A5 JP2007520453 A5 JP 2007520453A5
Authority
JP
Japan
Prior art keywords
fluorophenyl
oxo
hexane
ethyl acetate
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006539874A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007520453A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/037715 external-priority patent/WO2005047248A1/en
Publication of JP2007520453A publication Critical patent/JP2007520453A/ja
Publication of JP2007520453A5 publication Critical patent/JP2007520453A5/ja
Pending legal-status Critical Current

Links

JP2006539874A 2003-11-10 2004-11-10 4−ビアリーリル−1−フェニルアゼチジン−2−オン Pending JP2007520453A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US51869803P 2003-11-10 2003-11-10
US54957704P 2004-03-03 2004-03-03
US59252904P 2004-07-30 2004-07-30
US61400504P 2004-09-28 2004-09-28
PCT/US2004/037715 WO2005047248A1 (en) 2003-11-10 2004-11-10 4-biarylyl-1-phenylazetidin-2-ones

Publications (2)

Publication Number Publication Date
JP2007520453A JP2007520453A (ja) 2007-07-26
JP2007520453A5 true JP2007520453A5 (enExample) 2007-12-20

Family

ID=34596124

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006539874A Pending JP2007520453A (ja) 2003-11-10 2004-11-10 4−ビアリーリル−1−フェニルアゼチジン−2−オン

Country Status (21)

Country Link
US (2) US7320972B2 (enExample)
EP (1) EP1682499B1 (enExample)
JP (1) JP2007520453A (enExample)
KR (1) KR20070050861A (enExample)
AT (1) ATE369335T1 (enExample)
AU (1) AU2004288822A1 (enExample)
BR (1) BRPI0416361A (enExample)
CA (1) CA2545058A1 (enExample)
CY (1) CY1106982T1 (enExample)
DE (1) DE602004008100T2 (enExample)
DK (1) DK1682499T3 (enExample)
EA (1) EA010026B1 (enExample)
ES (1) ES2291974T3 (enExample)
IL (1) IL175414A0 (enExample)
MA (1) MA28216A1 (enExample)
MX (1) MXPA06005106A (enExample)
NO (1) NO20062665L (enExample)
NZ (1) NZ546940A (enExample)
PL (2) PL1682499T3 (enExample)
PT (1) PT1682499E (enExample)
WO (1) WO2005047248A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
EP1682499B1 (en) * 2003-11-10 2007-08-08 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-ones
WO2005061452A1 (en) 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
WO2006086562A2 (en) * 2005-02-09 2006-08-17 Microbia, Inc. Phenylazetidinone derivatives
WO2006102674A2 (en) * 2005-03-24 2006-09-28 Microbia, Inc. Diphenylheterocycle cholesterol absorption inhibitors
EP1877067A1 (en) * 2005-04-26 2008-01-16 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-one glucuronide derivatives for hypercholesterolemia
WO2006121861A2 (en) * 2005-05-05 2006-11-16 Microbia, Inc. Biphenylazetidinone cholesterol absorption inhibitors
TW200726746A (en) 2005-05-06 2007-07-16 Microbia Inc Processes for production of 4-biphenylylazetidin-2-ones
CA2608108A1 (en) * 2005-05-09 2006-11-16 Microbia, Inc. Organometal benzenephosphonate coupling agents
BRPI0608970A2 (pt) * 2005-05-11 2010-02-17 Microbia Inc processos para produção de 4-bifenililazetidin-2-onas fenólicas
JP2008540573A (ja) * 2005-05-13 2008-11-20 マイクロビア インコーポレーテッド 4−ビアリーリル−1−フェニラゼチジン−2−オン類
AU2006249905A1 (en) * 2005-05-25 2006-11-30 Microbia, Inc. Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
WO2006138163A2 (en) * 2005-06-15 2006-12-28 Merck & Co., Inc. Anti-hypercholesterolemic compounds
UY29607A1 (es) 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
ATE450526T1 (de) 2005-06-20 2009-12-15 Schering Corp Als antagonisten von histamin h3 geeignete piperidinderivate
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
MY148538A (en) 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
DE102005055726A1 (de) * 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
JO3598B1 (ar) * 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
WO2008057948A2 (en) * 2006-11-01 2008-05-15 Ironwood Pharmaceuticals, Inc. Processes for production of diphenylylazetidin-2-ones and related compounds
EP2086324A2 (en) * 2006-11-02 2009-08-12 Merck & Co., Inc. Heterocyclyl-substituted anti-hypercholesterolemic compounds
JPWO2008108486A1 (ja) * 2007-03-06 2010-06-17 帝人ファーマ株式会社 1−ビアリールアゼチジノン誘導体
US20080280836A1 (en) * 2007-05-08 2008-11-13 Morriello Gregori J Anti-hypercholesterolemic biaryl azetidinone compounds
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
WO2009126691A1 (en) * 2008-04-09 2009-10-15 Infinity Pharmaceuticals, Inc Inhibitors of fatty acid amide hydrolase
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010118159A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
EP2416660B1 (en) 2009-04-07 2014-07-02 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
ES2443016T3 (es) 2009-08-26 2014-02-17 Sanofi Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
AU2011213072C1 (en) 2010-02-03 2016-12-15 Infinity Pharmaceuticals, Inc. Fatty acid amide hydrolase inhibitors
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
DK3362462T3 (da) 2015-10-12 2021-10-11 Advanced Cell Diagnostics Inc In situ-detektion af nukleotidvarianter i prøver med højt støjniveau, og sammensætninger og fremgangsmåder relateret dertil

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37721A (en) * 1863-02-17 Improvement in hose-couplings
ATE158789T1 (de) 1991-07-23 1997-10-15 Schering Corp Substituierte beta-lactam-verbindungen als hypocholesterolemische mittel und verfahren zu deren herstellung
US5688787A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
US5688785A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5561227A (en) 1991-07-23 1996-10-01 Schering Corporation Process for the stereospecific synthesis of azetidinones
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
BR0116325A (pt) * 2000-12-21 2003-10-14 Aventis Pharma Gmbh 1,2-difenilazetidinonas, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação para o tratamento de distúrbios do metabolismo de lipìdios
AU2002240050A1 (en) * 2001-01-26 2002-08-06 Schering Corporation Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
TWI291957B (en) * 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
ATE411018T1 (de) * 2001-09-21 2008-10-15 Schering Corp Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US7176193B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176194B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
US20070135357A1 (en) * 2003-10-30 2007-06-14 Sings Heather L Anti-hypercholesterolemic compounds
EP1682499B1 (en) * 2003-11-10 2007-08-08 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-ones
BRPI0608970A2 (pt) * 2005-05-11 2010-02-17 Microbia Inc processos para produção de 4-bifenililazetidin-2-onas fenólicas
AU2006249905A1 (en) * 2005-05-25 2006-11-30 Microbia, Inc. Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
DE102005055726A1 (de) * 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US20080280836A1 (en) * 2007-05-08 2008-11-13 Morriello Gregori J Anti-hypercholesterolemic biaryl azetidinone compounds

Similar Documents

Publication Publication Date Title
JP2007520453A5 (enExample)
CN102675321B (zh) 一种替卡格雷的制备方法
JP2008094834A5 (enExample)
JP2012510502A5 (enExample)
JP2012526086A5 (enExample)
CN104761583A (zh) 含磷的α-酮酸的制造方法
JP2008517020A5 (enExample)
CN104030989A (zh) 一种瑞舒伐他汀钙的制备方法
USRE39333E1 (en) Process for the preparation of 5-hydroxy-3-oxopentanoic acid derivatives
JP2006528215A5 (enExample)
CN102796036B (zh) 一种阿托伐他汀钙的制备方法
JP6240346B2 (ja) ロスバスタチンカルシウムを製造するための中間体化合物、及びそれを用いてロスバスタチンカルシウムを製造する方法
JP5180289B2 (ja) キラル補助剤を用いた4−bmaの立体選択的製造方法
CN101376643A (zh) 一种碳青霉烯类青霉素厄他培南的中间体的制备方法
JP2013514344A (ja) 4−ブロモメチル−[1,1’−ビフェニル]−2’−カルボニトリルの調製方法
CN101376641B (zh) 碳青霉烯类青霉素厄他培南的中间体及其制备方法和应用
CN101376642B (zh) 碳青霉烯类青霉素厄他培南的中间体及其制备方法和应用
CN104725256A (zh) 一种联苯丙氨酸衍生物的制备方法
JP2004534040A (ja) 2−ヒドロキシ−4−フェニル酪酸エステルの立体選択的合成
JP2007503406A5 (enExample)
JP2004026660A5 (enExample)
JP2005314260A5 (enExample)
JP2006516588A5 (enExample)
JP3543383B2 (ja) β−ケトホスホナ−ト誘導体の製造方法
JP2005501812A (ja) 3−(z)−プロペニルセフェム化合物の選択的な製造方法